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OBJECTIVE — To describe the predictive relationships of selected sociodemographic, bio-
medical, and psychosocial variables to reluctance to use insulin among patients with type 2
diabetes.
RESEARCH DESIGN AND METHODS — A total of 178 patients with type 2 diabetes
participatedinthiscross-sectional,observationalstudy.Datawereobtainedbypatientinterview
usingvalidatedmeasuresofdiabetesattitude,knowledge,self-efﬁcacy,carecommunication,and
perceived barriers to treatment, as well as sociodemographic and biomedical data.
RESULTS — Women and ethnic minorities with type 2 diabetes have more psychological
barrierstoinsulintreatment(P0.05).Theﬁnalregressionmodelshowedthatindividualswho
believed in the value of tight glucose control, had strong self-efﬁcacy, and had better interper-
sonalprocesseswiththeirhealthcareproviderswerelessreluctanttouseinsulintreatment(R
2
0.403; P  0.0001).
CONCLUSIONS — Diabetes self-efﬁcacy and better interaction with clinicians were impor-
tant in decreasing patients’ reluctance to use insulin, known as psychological insulin resistance.
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D
espite the known beneﬁts of insu-
lin, many patients are reluctant to
use insulin therapy (1–3). A pa-
tient’sreluctancetoinitiateinsulinmaybe
called “psychological insulin resistance”
(PIR).
Little is known about what factors in-
ﬂuence PIR. We examined the relation-
ships among PIR, sociodemographic,
biomedical, and psychosocial factors
identiﬁed in previous studies (4–7) and
tested a predictive model of PIR.
RESEARCH DESIGN AND
METHODS— A descriptive correla-
tionalcross-sectionalsurveyof178adults
recruited from urban residential areas of
the San Francisco Bay Area was con-
ducted. The participants were recruited
through ﬂyers posted at two adult general
internal medicine clinics, the Diabetes
Teaching Center of a large west coast ac-
ademicmedicalcenter,twolocalcommu-
nity clinics, and three local churches. The
study was approved by the institutional
review board of the academic medical
center,andallparticipantsprovidedwrit-
ten informed consent. Inclusion criteria
were age 18 years or older, diagnosed
with type 2 diabetes, being treated with
diabeticoralagents,andabletospeakEn-
glish.Patientswithtype1diabetes,severe
psychiatric disease (e.g., active schizo-
phrenia and drug dependency), or de-
mentia and those on current insulin
treatment were excluded. Medical
records were reviewed for clinical data,
and data were collected in doctor’s ofﬁces
by face-to-face interview or by phone us-
ing the following validated question-
naires: Diabetes Attitude Scale (DAS-3)
(8); Diabetes Knowledge Test (DKT) (9);
Diabetes Self-Efﬁcacy Scale (DSES) (10);
Interpersonal Processes of Care Sur-
vey-18 (IPC-18) (11); and Barriers to In-
sulin Treatment (BIT) scale (12).
Statistical analyses were performed
using SPSS version 15.0. Results were de-
scribed using Pearson correlation coefﬁ-
cients, Spearman rank correlation test,
ANOVA, two-group t test, and hierarchi-
calmultipleregression.Alltestsweretwo-
sided, and type I error was controlled at
the 0.05 level. Because three instruments
with ﬁve to seven subscales were used, a
two-step approach was used to develop
the ﬁnal multivariate model. First, we
constructedaseparatemultivariatemodel
for each of the three instruments in order
to choose signiﬁcant subscales (P0.05)
related to PIR from each instrument for
inclusion into the ﬁnal model. We con-
structed a hierarchical multiple regres-
sion to examine the effects of the four
demographicvariables(selectedfromsig-
niﬁcant correlation [P  0.05] with PIR),
the seven subscales, and possible interac-
tions among the IPC subscales, i.e., the
DAS-3 and DSES subscales on PIR.
RESULTS— Ofthe196potentialindi-
vidualswhowereapproachedandinvited
to participate in this study, 10 did not
meet the inclusion criteria and 8 declined
participation. A total of 178 patients con-
sented and participated. Study sample
characteristics and the descriptive statis-
tics for the DAS 3, DKT, DSES, IPC, and
BIT are presented in Table 1.
The overall PIR across respondents
was moderate, with a mean of 4.89 on a
scaleof1to10.Womenhadhigherfearof
injections (P  0.001) stigmatization
(P  0.01) and overall a higher mean BIT
score, reﬂecting more reluctance to use
insulin than men (P  0.008). Asians had
signiﬁcantlyhigherfearofinjections(P
0.003) and expected greater hardship in
using insulin than whites (P  0.03).
Overall,Asiansweremorereluctanttouse
insulin than whites (P  0.012). Other
minoritygroups(Hispanics,AmericanIn-
dians, and Paciﬁc Islanders) also had sig-
niﬁcantly higher fear of injection than
whites (P  0.031).
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1University of California, San Francisco, School of Nursing, San Francisco, California; and the
2University of California, San Francisco, School of Pharmacy, San Francisco, California.
Corresponding author: Soohyun Nam, soohnam@gmail.com.
Received 19 January 2010 and accepted 23 April 2010. Published ahead of print at http://care.
diabetesjournals.org on 30 April 2010. DOI: 10.2337/dc10-0099.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
BRIEF REPORT
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 1747AllsubscalesoftheIPChadanegative
association with PIR (P  0.01), indicat-
ing that better perceived interaction with
health care providers was associated with
lowerlevelofPIR.Intheﬁnalmultivariate
model, the linear combination of the pre-
dictors in the model was signiﬁcantly re-
lated to PIR (R
2  0.403; P  0.0001).
Individuals who believed in the value of
tightglucosecontrolandhadbetterinter-
personal processes with their health care
providers were less reluctant to use insu-
lintreatment.Theinverserelationshipbe-
tween PIR and exercise self-efﬁcacy was
stronger for those with greater interper-
sonal communication processes scores
with health care providers. Those with
strongerexerciseself-efﬁcacywerelessre-
luctant to initiate insulin treatment. This
relationship is modiﬁed by interpersonal
care process with health care providers.
CONCLUSIONS — Our ﬁndings
showed that adults with type 2 diabetes
treated by oral agents had moderate PIR,
which is consistent with results in a prior
study by Polonsky et al. (13). Fear of hy-
poglycemia was the strongest barrier to
insulin treatment while expected hard-
ship in using insulin inﬂuenced the PIR
minimally. Fear of hypoglycemia is im-
portanttodiscusswithpatientstoeducate
them that hypoglycemic episodes can of-
ten be avoided through adjustment of
insulin and careful vigilance in self-
monitoring of blood glucose.
Women were more reluctant to begin
insulin treatment and indicated a greater
fear of injection and social stigmatization in
using insulin than men. These results are of
particular concern, because it has been
shown that women with diabetes are less
likely than men to have A1C 7% and are
at greater risk of diabetes-associated coro-
nary heart disease than men (14).
As demonstrated in a previous study
(13), ethnic minorities had greater PIR
than whites. Asians and other nonblack
minority groups had signiﬁcantly higher
fear of injections and expected greater
hardship in using insulin than whites.
This study has some limitations. Our
participants had relatively good glycemic
control with their oral medications. The
studyﬁndingsmaynotbegeneralizableto
the patients with severe hyperglycemia.
Futureresearchisneededtobetterunder-
stand PIR. The BIT was used as a surro-
gate variable to measure PIR, and thus we
cannot conclude that patients with many
barriers to insulin treatment will actually
reject insulin treatment when it is recom-
Table 1—Characteristics of the study sample (n  178) and descriptive statistics for the
instruments
Age (years) 64.3  13.54
A1C (%)* 6.98  0.99 (5.2–11.0)
Duration of diabetes (years) 7.03  4.07
Sex
Male 82 (46.1)
Female 96 (53.9)
Race
Asians 58 (32.6)
Blacks 45 (25.3)
Whites 56 (31.5)
Other† 19 (10.6)
Education
Less than high school 14 (7.9)
High school graduate 36 (20.2)
Some college, 1–3 years 65 (36.5)
Bachelor’s degree 36 (20.2)
Graduate degree 27 (15.2)
Income (U.S.D.)
Less than $10,000 28 (15.7)
$10,000$29,999 41 (23.0)
$30,000$49,999 37 (20.8)
$50,000$69,999 21 (11.8)
$70,000$99,999 19 (10.7)
Greater than $100,000 32 (18.0)
DAS-3 (scale range)
Need for special training (1–5) 4.20  0.37 (2.4–5.0)
Seriousness of diabetes (1–5) 3.75  0.52 (2.57–5.0)
Value of tight control (1–5) 3.71  0.50 (2.14–5.0)
Psychosocial impact of diabetes (1–5) 3.68  0.57 (2.0–5.0)
Patient autonomy (1–5) 3.68  0.42 (2.5–4.75)
DKT (0–100%) 67.22  18.88 (21.43–100.0)
DSES (scale range)
Sum (1–6) 4.54  0.77 (2.06–5.94)
Diabetes routine (1–6) 5.04  0.85 (1.75–6.0)
Self-treat (1–6) 4.62  1.02 (1.0–6.0)
Certainty (1–6) 4.20  1.23 (1.25–6.0)
Diet (1–6) 4.27  1.28 (1.0–6.0)
Exercise (1–6) 4.41  1.44 (1.0–6.0)
IPC-18 (scale range)
Communication
Lack of clarity (1–5) 4.03  0.99 (1.0–5.0)
Elicited concern (1–5) 4.16  0.85 (1.33–5.0)
Explained results (1–5) 4.46  0.81 (1.0–5.0)
Decision making
Worked together (1–5) 3.79  1.01 (1.0–5.0)
Interpersonal style
Compassionate, respectful (1–5) 4.34  0.72 (1.33–5.0)
Discriminated due to race/ethnicity (1–5) 4.76  0.60 (2.0–5.0)
Disrespectful ofﬁce staff (1–5) 4.50  0.80 (1.5–5.0)
BIT (scale range)
Sum (1–10) 4.89  1.63 (1.0–10.0)
Fear of injection (1–10) 4.44  2.87 (1.0–10.0)
Expectations regarding positive outcome (1–10) 5.49  2.13 (1.0–10.0)
Expected hardship (1–10) 3.34  2.60 (1.0–10.0)
Stigmatization (1–10) 5.31  2.55 (1.0–10.0)
Fear of hypoglycemia (1–10) 6.38  2.71 (1.0–10.0)
(continued)
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However, Petrak et al. (12) previously
demonstrated the clear predictive validity
of all BIT questionnaire scales to reluc-
tance to use insulin. Patients who pre-
ferred oral antidiabetic medications
consistently reported signiﬁcantly higher
barriers to insulin treatment than those
willing to move on to insulin.
In summary, patient self-management
educationthatisfocusedonimprovingself-
efﬁcacy, the consideration of sex and race
differences in PIR, and enhanced patient-
provider communications are necessary to
decrease PIR. Future research should be di-
rected toward understanding and promo-
tion of the interpersonal processes of care
between patients and their health care
providers and are needed for the devel-
opmentofinterventionstohelppatients
overcome the barriers to accepting in-
sulin therapy.
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Table 1—Continued
Number of comorbidities‡§
0 118 (66.3)
1 42 (23.6)
2 7 (3.9)
3 1 (0.6)
Missing 10 (5.6)
Number of microvascular diabetic complications‡
0 146 (82.0)
1 16 (9.0)
2 5 (2.8)
3 1 (0.6)
Missing 10 (5.6)
Data are means  SD (range), or n (%). *n  158. †Other: American Indians or Alaska Natives, Native
Hawaiian, or Paciﬁc Islander. ‡n  168. §Comorbidities: congestive heart failure, chronic obstructive
pulmonary disease, and arthritis.
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